-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2022 American Gastroenterology Society Annual Meeting and Graduate Student Conference (ACG 2022) was held in Charlotte, North Carolina, on October 21~26, 2022, and this article summarizes
13 highlight studies at ACG 2022.
Upatinib has limited benefit in the treatment of ulcerative colitis and is dose-dependent
Upadacitinib is a Janus-activated kinase (JAK) inhibitor approved in the United States for the treatment of rheumatoid arthritis and psoriatic arthritis.
and is being studied for a variety of other diseases
.
The investigators performed a post-hoc analysis of the use of upatinib in patients with ulcerative colitis (UC): participants were randomized to placebo, uvpatinib 15 mg, or upatinib 30 mg for 52 weeks
of follow-up.
The results showed that the 30 mg dose resulted in significant improvement in patients, with clinical remission extended by approximately 1 month
compared to the 15 mg dose.
(References: Feagan BG, Parkes G, Juillerat P, et al.
Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 1.
）
Using virtual reality to treat dyspepsia A study that observed the efficacy of using virtual reality (VR) in the treatment of functional dyspepsia showed that cognitive behavioral therapy is very effective for a variety of diseases, especially irritable bowel syndrome (
irritable bowel syndrome，IBS）
。
This is a double-blind, randomized, controlled study that showed significant improvements in indigestion symptoms and quality of life outcomes with VR headsets and three different procedures
.
Cognitive behavioral therapy will appear more and more in the diagnosis and treatment of functional diseases, and we can continue to look forward to it
.
(References: Cangemi D, Montenegro M, Spiegel B, Lacy BE.
Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 3.
）
of high-quality index colonoscopy
One study looked at how high-quality index colonoscopies predicted a reduced risk of late outcomes in people without adenomas or serrated polyps at 10 years
.
The researchers surveyed 14,257 patients in the New Hampshire Colonoscopy Registry and found that the absolute risk of late outcome with high-quality testing was 4% — meaning adenoma detection rate was 25 percent or higher — compared with 6.
7 percent
if low-quality testing was performed.
(References: Anderson JC, Hisey W, Mackenzie T, Robinson C, Butterly LF.
) Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 7.
）
with early-onset colon cancer need genetic counseling, and researchers at Cleveland Clinic have conducted a long study
of early-onset colon cancer.
During this time, they noted that 1 in 5 young-onset colon cancer patients had a pathogenic germline variant (regardless of family history).
However, less than two-thirds of patients at the Cleveland Clinic are referred for genetic counseling and testing, making them aware of the shortcomings of their current work
.
For early-onset colorectal cancer (onset < 50 years of age), guidelines recommend that all patients should be referred for assessment<b20> of pathogenic germline variants.
(References: Syed H, Sommovilla J, McGee S, Heald B, Macaron C, Burke CA, Liska D.
Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 8.
）
studies on newly approved eosinophilic esophagitis therapies
Currently, dupilumab is approved in the United States for the treatment of eosinophilic esophagitis (EoE
).
Dupilumab is a fully human monoclonal antibody that blocks the shared receptor components of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are the main drivers of EoE type 2 inflammation
.
Two studies published data on the treatment of EoE at 24 weeks and 52 weeks, showing that dupilumab is administered once weekly and that treatment is effective and continuous
.
Notably, these were proton pump inhibitors (PPIs) who did not respond to treatment, and most also received a variety of other treatments
, including steroids.
Patients usually have more severe disease
.
Whether this new drug will need to be used for mild disease remains to be seen
.
(References: 1.
Dellon E, Rothenberg M, Bredenoord A, et al.
Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 11；2.
Dellon E, Rothenberg M, Collins MH, et al.
Program and abstracts of the American College of Gastroenterology 2022 Congress; October 21-26, 2022; Charlotte, North Carolina.
Abstract 52.
）
Reference: David A.
Johnson.
13 Highlights From the American College
of Gastroenterology's 2022 Meeting - Medscape - Nov 01, 2022.
This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
